Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 4;11(4):8281.
doi: 10.4081/hr.2019.8281. eCollection 2019 Nov 29.

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study

Vincenzo Accurso  1 , Marco Santoro  2 , Simona Raso  2 , Angelo Davide Contrino  1 , Paolo Casimiro  1 , Florinda Di Piazza  2 , Alessandro Perez  2 , Antonio Russo  2 , Sergio Siragusa  1
Affiliations

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study

Vincenzo Accurso et al. Hematol Rep. .

Abstract

Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.

Keywords: Polycythemia Vera; Splenomegaly; essential thrombocythemia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare no potential conflict of interest.

Figures

Figure 1.
Figure 1.
Survival in patients with splenomegaly versus patients without splenomegaly at diagnosis. In PV patients (A) and ET patients (B).
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405. - PubMed
    1. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-70. - PubMed
    1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901. - PubMed
    1. Bose P, Verstovsek S. Prognosis of primary myelofibrosis in the genomic era. Clin Lymphoma Myeloma Leuk 2016;16:S105-13. - PMC - PubMed
    1. Andriani A, Latagliata R, Anaclerico B, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. Am J Hematol 2016;91:318-21. - PubMed

LinkOut - more resources